Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.4564-4565 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4565 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 4564 |
| container_title | Blood |
| container_volume | 140 |
| creator | Chen, Wenming Fu, Chengcheng Fang, Baijun Liang, Aibin Xia, Zhongjun He, Yanjuan Lu, Jin Liu, Hui Hou, Ming Cai, Zhen Yang, Wei Hao, Siguo Jiang, Songfu Jing, Hongmei Liu, Jing Du, Xin Fu, Rong Mei, Heng Zhu, Zunmin Yang, Yanli Liu, Hong Yuan, Daijing Zhao, Hongxia Xiao, Jun Wang, Wei Wang, Huamao LI, Zonghai |
| description | |
| doi_str_mv | 10.1182/blood-2022-168610 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_168610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122035455</els_id><sourcerecordid>S0006497122035455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1850-f5f79e8afe771032d847e7464ee9dfa46dc0ebeb5c9cd4f909c23c169e3e12323</originalsourceid><addsrcrecordid>eNp9kDtOAzEYhC0EEuFxADqXUBhs71tUYQUEiYgohIZm5di_g5Gzjmxv0B6AilNwNU5CINRUU32jmQ-hE0bPGSv5xdw6pwinnBOWlzmjO2jAMl4SSjndRQNKaU7SqmD76CCEV0pZmvBsgD4mLyIA_nr_xI-xUz12Gt901vZ41C1Fi6_q8ZDMhF9ANO0C18MpmeEarA349BnWzksxj2IBLeBhF52FToI9w6bFExENtDHgNxNf8BSsWAVQF1PQXsjofI_HnY1mZQGPe7BuKY7QnhY2wPFfHqKnm-tZPSL3D7d39fCeSFZmlOhMFxWUQkNRMJpwVaYFFGmeAlRKizRXksIc5pmspEp1RSvJE8nyChJgPOHJIWLbXuldCB50s_JmKXzfMNr82Gx-bTY_NputzQ1zuWVgM2xtwDdBbu5JUMaDjI1y5h_6G_KKf3c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Chen, Wenming ; Fu, Chengcheng ; Fang, Baijun ; Liang, Aibin ; Xia, Zhongjun ; He, Yanjuan ; Lu, Jin ; Liu, Hui ; Hou, Ming ; Cai, Zhen ; Yang, Wei ; Hao, Siguo ; Jiang, Songfu ; Jing, Hongmei ; Liu, Jing ; Du, Xin ; Fu, Rong ; Mei, Heng ; Zhu, Zunmin ; Yang, Yanli ; Liu, Hong ; Yuan, Daijing ; Zhao, Hongxia ; Xiao, Jun ; Wang, Wei ; Wang, Huamao ; LI, Zonghai</creator><creatorcontrib>Chen, Wenming ; Fu, Chengcheng ; Fang, Baijun ; Liang, Aibin ; Xia, Zhongjun ; He, Yanjuan ; Lu, Jin ; Liu, Hui ; Hou, Ming ; Cai, Zhen ; Yang, Wei ; Hao, Siguo ; Jiang, Songfu ; Jing, Hongmei ; Liu, Jing ; Du, Xin ; Fu, Rong ; Mei, Heng ; Zhu, Zunmin ; Yang, Yanli ; Liu, Hong ; Yuan, Daijing ; Zhao, Hongxia ; Xiao, Jun ; Wang, Wei ; Wang, Huamao ; LI, Zonghai</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-168610</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.4564-4565</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1850-f5f79e8afe771032d847e7464ee9dfa46dc0ebeb5c9cd4f909c23c169e3e12323</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Chen, Wenming</creatorcontrib><creatorcontrib>Fu, Chengcheng</creatorcontrib><creatorcontrib>Fang, Baijun</creatorcontrib><creatorcontrib>Liang, Aibin</creatorcontrib><creatorcontrib>Xia, Zhongjun</creatorcontrib><creatorcontrib>He, Yanjuan</creatorcontrib><creatorcontrib>Lu, Jin</creatorcontrib><creatorcontrib>Liu, Hui</creatorcontrib><creatorcontrib>Hou, Ming</creatorcontrib><creatorcontrib>Cai, Zhen</creatorcontrib><creatorcontrib>Yang, Wei</creatorcontrib><creatorcontrib>Hao, Siguo</creatorcontrib><creatorcontrib>Jiang, Songfu</creatorcontrib><creatorcontrib>Jing, Hongmei</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Du, Xin</creatorcontrib><creatorcontrib>Fu, Rong</creatorcontrib><creatorcontrib>Mei, Heng</creatorcontrib><creatorcontrib>Zhu, Zunmin</creatorcontrib><creatorcontrib>Yang, Yanli</creatorcontrib><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Yuan, Daijing</creatorcontrib><creatorcontrib>Zhao, Hongxia</creatorcontrib><creatorcontrib>Xiao, Jun</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Wang, Huamao</creatorcontrib><creatorcontrib>LI, Zonghai</creatorcontrib><title>Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kDtOAzEYhC0EEuFxADqXUBhs71tUYQUEiYgohIZm5di_g5Gzjmxv0B6AilNwNU5CINRUU32jmQ-hE0bPGSv5xdw6pwinnBOWlzmjO2jAMl4SSjndRQNKaU7SqmD76CCEV0pZmvBsgD4mLyIA_nr_xI-xUz12Gt901vZ41C1Fi6_q8ZDMhF9ANO0C18MpmeEarA349BnWzksxj2IBLeBhF52FToI9w6bFExENtDHgNxNf8BSsWAVQF1PQXsjofI_HnY1mZQGPe7BuKY7QnhY2wPFfHqKnm-tZPSL3D7d39fCeSFZmlOhMFxWUQkNRMJpwVaYFFGmeAlRKizRXksIc5pmspEp1RSvJE8nyChJgPOHJIWLbXuldCB50s_JmKXzfMNr82Gx-bTY_NputzQ1zuWVgM2xtwDdBbu5JUMaDjI1y5h_6G_KKf3c</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Chen, Wenming</creator><creator>Fu, Chengcheng</creator><creator>Fang, Baijun</creator><creator>Liang, Aibin</creator><creator>Xia, Zhongjun</creator><creator>He, Yanjuan</creator><creator>Lu, Jin</creator><creator>Liu, Hui</creator><creator>Hou, Ming</creator><creator>Cai, Zhen</creator><creator>Yang, Wei</creator><creator>Hao, Siguo</creator><creator>Jiang, Songfu</creator><creator>Jing, Hongmei</creator><creator>Liu, Jing</creator><creator>Du, Xin</creator><creator>Fu, Rong</creator><creator>Mei, Heng</creator><creator>Zhu, Zunmin</creator><creator>Yang, Yanli</creator><creator>Liu, Hong</creator><creator>Yuan, Daijing</creator><creator>Zhao, Hongxia</creator><creator>Xiao, Jun</creator><creator>Wang, Wei</creator><creator>Wang, Huamao</creator><creator>LI, Zonghai</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma</title><author>Chen, Wenming ; Fu, Chengcheng ; Fang, Baijun ; Liang, Aibin ; Xia, Zhongjun ; He, Yanjuan ; Lu, Jin ; Liu, Hui ; Hou, Ming ; Cai, Zhen ; Yang, Wei ; Hao, Siguo ; Jiang, Songfu ; Jing, Hongmei ; Liu, Jing ; Du, Xin ; Fu, Rong ; Mei, Heng ; Zhu, Zunmin ; Yang, Yanli ; Liu, Hong ; Yuan, Daijing ; Zhao, Hongxia ; Xiao, Jun ; Wang, Wei ; Wang, Huamao ; LI, Zonghai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1850-f5f79e8afe771032d847e7464ee9dfa46dc0ebeb5c9cd4f909c23c169e3e12323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Wenming</creatorcontrib><creatorcontrib>Fu, Chengcheng</creatorcontrib><creatorcontrib>Fang, Baijun</creatorcontrib><creatorcontrib>Liang, Aibin</creatorcontrib><creatorcontrib>Xia, Zhongjun</creatorcontrib><creatorcontrib>He, Yanjuan</creatorcontrib><creatorcontrib>Lu, Jin</creatorcontrib><creatorcontrib>Liu, Hui</creatorcontrib><creatorcontrib>Hou, Ming</creatorcontrib><creatorcontrib>Cai, Zhen</creatorcontrib><creatorcontrib>Yang, Wei</creatorcontrib><creatorcontrib>Hao, Siguo</creatorcontrib><creatorcontrib>Jiang, Songfu</creatorcontrib><creatorcontrib>Jing, Hongmei</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Du, Xin</creatorcontrib><creatorcontrib>Fu, Rong</creatorcontrib><creatorcontrib>Mei, Heng</creatorcontrib><creatorcontrib>Zhu, Zunmin</creatorcontrib><creatorcontrib>Yang, Yanli</creatorcontrib><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Yuan, Daijing</creatorcontrib><creatorcontrib>Zhao, Hongxia</creatorcontrib><creatorcontrib>Xiao, Jun</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Wang, Huamao</creatorcontrib><creatorcontrib>LI, Zonghai</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Wenming</au><au>Fu, Chengcheng</au><au>Fang, Baijun</au><au>Liang, Aibin</au><au>Xia, Zhongjun</au><au>He, Yanjuan</au><au>Lu, Jin</au><au>Liu, Hui</au><au>Hou, Ming</au><au>Cai, Zhen</au><au>Yang, Wei</au><au>Hao, Siguo</au><au>Jiang, Songfu</au><au>Jing, Hongmei</au><au>Liu, Jing</au><au>Du, Xin</au><au>Fu, Rong</au><au>Mei, Heng</au><au>Zhu, Zunmin</au><au>Yang, Yanli</au><au>Liu, Hong</au><au>Yuan, Daijing</au><au>Zhao, Hongxia</au><au>Xiao, Jun</au><au>Wang, Wei</au><au>Wang, Huamao</au><au>LI, Zonghai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>4564</spage><epage>4565</epage><pages>4564-4565</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-168610</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.4564-4565 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_168610 |
| source | Alma/SFX Local Collection; EZB Electronic Journals Library |
| title | Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A24%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20%E2%85%A1%20Study%20of%20Fully%20Human%20BCMA-Targeting%20CAR-T%20Cells%20(Zevorcabtagene%20Autoleucel)%20in%20Patients%20with%20Relapsed/Refractory%20Multiple%20Myeloma&rft.jtitle=Blood&rft.au=Chen,%20Wenming&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=4564&rft.epage=4565&rft.pages=4564-4565&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-168610&rft_dat=%3Celsevier_cross%3ES0006497122035455%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122035455&rfr_iscdi=true |